Efficacy of High Dose Dexamethasone in Prevention of Hypersensitivity Reaction Induced by Oxaliplatin: A Randomized Double-Blind Controlled Trial

Sisaket Hospital0 sites194 target enrollmentMarch 19, 2024

Overview

No summary available.

Registry

who.int

Start Date

March 19, 2024

End Date

January 31, 2025

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Sisaket Hospital

•1\. Patients with cancer, aged at least 18 years, diagnosed with colorectal cancer who have received oxaliplatin
•2\. In the case of metastatic disease, participants must not have received oxaliplatin before
•3\. In the case of adjuvant oxaliplatin treatment, it must be stopped at least 6 months before entering the study
•4\. ECOG performance status 0\-2
•4\. Life expectancymmore than 12 weeks
•5\. Blood test results: ANC more than 1,000/mm3, platelet more than 75,000, Hb more than 8 g/dL, total bilirubin more than 2, Cr less than 1\.5 times the upper normal limit
•6\. Patients who have signed informed consent to participate in the research project

•1\. Patients with a history of severe allergic reactions to oxaliplatin or other platinum\-containing compounds
•2\. Patients with severe hypersensitivity to other drugs or excipients in the study drug
•3\. Patients with uncontrolled underlying diseases
•4\. Patients with multiple primary cancers in the past 5 years
•5\. Patients with pleural effusion, pericardial effusion, or ascites that require drainage
•6\. Patients with significant mental or psychological illness